Document Detail


Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study.
MedLine Citation:
PMID:  12824745     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation. The present study was designed to evaluate the effects of atypical neuroleptics in comparison with a conventional dopamine antagonist neuroleptic (haloperidol) on several dimensions of psychomotor performance (visual perception, attention, reaction time, and sensorimotor performance) considered to be of relevance in evaluating driving fitness. Psychomotor performance was assessed by means of the ART 90, a computerized Act and React Test which is generally used in diagnosis of psychomotor performance. The 49 participating patients were examined at discharge following psychopathological stabilisation; 20 received haloperidol, 29 received an atypical neuroleptic. Our findings demonstrate a remarkably reduced psychomotor performance in the haloperidol-treated group of schizophrenic patients compared with patients treated with atypical neuroleptics. Only 1 (5%) subject passed all subtests without major failures and could be regarded as competent to drive. Among patients with atypical neuroleptics, 7 patients (24%) passed all test parameters without major failures.
Authors:
Sabine Kagerer; Catja Winter; Hans-Jürgen Möller; Michael Soyka
Related Documents :
9465155 - Role of polymerase chain reaction in the diagnosis of early leprosy.
10601405 - In vivo investigation of white matter pathology in schizophrenia with magnetisation tra...
472735 - Plasma beta-endorphin immunoreactivity in schizophrenia.
11440775 - Lower prolactin bioactivity in unmedicated schizophrenic patients.
22859345 - Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is no...
21897515 - Prolonged vertigo and ataxia after mandibular nerve block for treatment of trigeminal n...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Neuropsychobiology     Volume:  47     ISSN:  0302-282X     ISO Abbreviation:  Neuropsychobiology     Publication Date:  2003  
Date Detail:
Created Date:  2003-06-25     Completed Date:  2003-08-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7512895     Medline TA:  Neuropsychobiology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  212-8     Citation Subset:  IM    
Copyright Information:
Copyright 2003 S. Karger AG, Basel
Affiliation:
Psychiatric Hospital, Dtstion C4, University of Munich, Nussbaumstrasse 7, DE-80336 Munich, Germany. Sabine.Kagerer@psy.med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / adverse effects*,  therapeutic use
Automobile Driving*
Dopamine Antagonists / adverse effects*,  therapeutic use
Female
Haloperidol / adverse effects*,  therapeutic use
Humans
Male
Middle Aged
Psychomotor Performance / drug effects*
Schizophrenia / drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Dopamine Antagonists; 52-86-8/Haloperidol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cognitive dysfunction in cortical cerebellar atrophy correlates with impairment of the inhibitory sy...
Next Document:  Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases